HER2 overexpression is reported in about 15% to 20% of breast cancer patients.23 A positive HER2 status was related to a positive ALNM.24 HER3 overexpression is seen in about 80% of primary colorectal cancer cases and this corresponds to lymph node metastasis.25 However, no previous studies have analyzed the molecular status of ALNM and mutations in the EGFR in patients with breast cancer. Here, ERBB3 is linked to metastatic malignant neoplasm in the lymph nodes.